Urogen Pharma Ltd. (URGN)
Urogen Pharma (URGN) Reports Q1 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.97 per share a year ago.
Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last?
Urogen Pharma (URGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy
I maintain a "Strong Buy" rating on UroGen Pharma despite a ~20% drop, emphasizing the high-risk nature of early-stage biotechs in today's volatile market. UroGen's ~$0.43 billion market cap undervalues its potential, especially with the upcoming FDA decision on UGN-102 for low-grade intermediate-risk non-muscle invasive bladder cancer. UGN-102's pivotal trial results show promising data, with an 80.6% duration of response at 18 months, making a strong case for FDA approval.
UroGen Pharma Ltd. (URGN) Q4 2024 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN ) Q4 2024 - Earnings Conference Call March 10, 2025 10:00 AM ET Company Participants Vincent Perrone - Head of IR Liz Barrett - President and CEO Mark Schoenberg - CMO David Lin - CCO Chris Degnan - CFO Conference Call Participants Michael Schmidt - Guggenheim Raghuram Selvaraju - H.
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.72 per share a year ago.
UroGen: Upcoming PDUFA, Some Concerns Remain
UroGen's Jelmyto, a gel-based mitomycin product for LG-UTUC, achieved $25.2mn in Q3 2024, marking a 20% YoY increase. Lead candidate UGN-102 shows promise in treating low-grade intermediate risk NMIBC, with significant clinical trial success and a PDUFA date set for June 13, 2025. Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva.
Wall Street Analysts Believe Urogen Pharma (URGN) Could Rally 209.92%: Here's is How to Trade
The mean of analysts' price targets for Urogen Pharma (URGN) points to a 209.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
UroGen Pharma: Choice Based On Near Term High Value PDUFA
Urogen's UGN-102 for bladder cancer presents a $5 billion market opportunity, prompting a continued "Strong Buy" rating despite past misjudgments. FDA approval by 06/2025 is crucial, with UGN-102 potentially being the first FDA-approved treatment for low-grade intermediate-risk NMIBC. Urogen's financials show a cash runway of over 2 years, with additional borrowing contingent on timely FDA approval.
UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN ) Q3 2024 Earnings Call Transcript November 6, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Liz Barrett - President and CEO Mark Schoenberg - CMO David Lin - CCO Chris Degnan - CFO Conference Call Participants Tara Bancroft - TD Cowen Ram Selvaraju - H.
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.68 per share a year ago.
UroGen Pharma Ltd. (URGN) Q2 2024 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN ) Q2 2024 Earnings Call August 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head, Investor Relations Liz Barrett - President and Chief Executive Officer Mark Schoenberg - Chief Medical Officer David Lin - Chief Commercial Officer Dong Kim - Chief Financial Officer Conference Call Participants Tara Bancroft - TD Cowen Raghuram Selvaraju - H.C.
Urogen Pharma (URGN) Reports Q2 Loss, Misses Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.03 per share a year ago.
